InvisiMask™ | COVID-19 nasal spray | Eureka Therapeutics

The InvisiMask nasal spray is an investigational daily human antibody nasal spray designed to neutralize SARS-CoV-2, the virus that causes COVID-19, from airborne droplets and particles in the nasal cavity, the primary entry point of SARS-CoV-2 infection.

At the lowest dose of 25μg, the antibodies provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested (107 virus particles administered intra-nasally). 

Source: InvisiMask™ | COVID-19 nasal spray | Eureka Therapeutics